|
Market Closed -
Euronext Paris
11:55:00 2026-10-16 EDT
|
5-day change | 1st Jan Change | ||
| 0.6880 EUR | +0.88% |
|
+0.44% | -28.33% |
| 09-25 | Transgene provides update on its operations |  |
| 09-08 | Transgene Expands ProBioGen Partnership With Additional License | MT |
Projected Income Statement: Transgene
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 17.41 | 10.34 | 7.9 | 6.353 | 7.21 | 7.2 | 7.2 | 57.2 |
| Change | - | -40.6% | -23.63% | -19.58% | 13.49% | -0.14% | 0% | 694.44% |
| EBITDA 1 | -21 | -28.22 | -28.48 | -34.38 | -33.73 | -43.6 | -70.1 | -23.6 |
| Change | - | -34.35% | -0.91% | -20.73% | 1.87% | -29.25% | -60.78% | 66.33% |
| EBIT 1 | -23.52 | -29.9 | -30.05 | -35.66 | -35.06 | -44.3 | -70.8 | -29.3 |
| Change | - | -27.12% | -0.48% | -18.67% | 1.68% | -26.36% | -59.82% | 58.62% |
| Interest Paid | 3.989 | -0.804 | 7.719 | 1.687 | -2.465 | - | - | - |
| Earnings before Tax (EBT) | -19.54 | -32.8 | - | - | - | - | - | - |
| Change | - | -67.92% | - | - | - | - | - | - |
| Net income 1 | -19.54 | -32.8 | -22.33 | -33.97 | -37.52 | -38.2 | -61.6 | -25.3 |
| Change | - | -67.92% | 31.94% | -52.15% | -10.46% | -1.8% | -61.26% | 58.93% |
| Announcement Date | 3/16/22 | 3/16/23 | 3/27/24 | 3/27/25 | 3/24/26 | - | - | - |
1EUR in Million
Estimates
Forecast Balance Sheet: Transgene
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | -32.9 | -13.3 | 1.63 | -6.27 | -110 | -69.2 | -7.7 | 18.6 |
| Change | - | 59.57% | 112.26% | -484.66% | -1,654.39% | 36.98% | 88.87% | 341.56% |
| Announcement Date | 3/16/22 | 3/16/23 | 3/27/24 | 3/27/25 | 3/24/26 | - | - | - |
1EUR in Million
Estimates
Cash Flow Forecast: Transgene
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| CAPEX 1 | 0.686 | 1.535 | - | 3.066 | 106 | 1 | 1 | 7 |
| Change | - | 123.76% | - | - | 3,355.68% | -99.06% | 0% | 600% |
| Free Cash Flow (FCF) 1 | -32.61 | -21.84 | -0.099 | -26.75 | -143 | -39.7 | -60.4 | -25.1 |
| Change | - | 33.04% | 99.55% | -26,924.24% | -434.49% | 72.24% | -52.14% | 58.44% |
| Announcement Date | 3/16/22 | 3/16/23 | 3/27/24 | 3/27/25 | 3/24/26 | - | - | - |
1EUR in Million
Estimates
Forecast Financial Ratios: Transgene
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||
| EBITDA Margin (%) | -120.62% | -272.8% | -360.44% | -541.11% | -467.86% | -605.56% | -973.61% | -41.26% |
| EBIT Margin (%) | -135.1% | -289.1% | -380.34% | -561.28% | -486.26% | -615.28% | -983.33% | -51.22% |
| EBT Margin (%) | -112.19% | -317.13% | - | - | - | - | - | - |
| Net margin (%) | -112.19% | -317.13% | -282.63% | -534.72% | -520.44% | -530.56% | -855.56% | -44.23% |
| FCF margin (%) | -187.3% | -211.12% | -1.25% | -421.12% | -1,983.31% | -551.39% | -838.89% | -43.88% |
| FCF / Net Income (%) | 166.94% | 66.57% | 0.44% | 78.76% | 381.08% | 103.93% | 98.05% | 99.21% |
Profitability | ||||||||
| ROA | - | - | - | - | - | - | - | - |
| ROE | -33.13% | -62.45% | - | - | -54.8% | -37.3% | - | - |
Financial Health | ||||||||
| Leverage (Debt/EBITDA) | - | - | -0.06x | - | - | - | - | -0.79x |
| Debt / Free cash flow | - | - | -16.45x | - | - | - | - | -0.74x |
Capital Intensity | ||||||||
| CAPEX / Current Assets (%) | 3.94% | 14.84% | - | 48.26% | 1,469.5% | 13.89% | 13.89% | 12.24% |
| CAPEX / EBITDA (%) | -3.27% | -5.44% | - | -8.92% | -314.09% | -2.29% | -1.43% | -29.66% |
| CAPEX / FCF (%) | -2.1% | -7.03% | - | -11.46% | -74.09% | -2.52% | -1.66% | -27.89% |
Items per share | ||||||||
| Cash flow per share 1 | - | - | - | - | - | - | - | - |
| Change | - | - | - | - | - | - | - | - |
| Dividend per Share 1 | - | - | - | - | - | - | - | - |
| Change | - | - | - | - | - | - | - | - |
| Book Value Per Share 1 | 0.6887 | 0.3787 | 0.1553 | 0.1149 | 0.8423 | 0.3 | 0.08 | -0.01 |
| Change | - | -45.01% | -58.99% | -26.01% | 633.07% | -64.38% | -73.33% | -112.5% |
| EPS 1 | -0.21 | -0.33 | -0.22 | -0.29 | -0.26 | -0.14 | -0.22 | -0.09 |
| Change | - | -57.14% | 33.33% | -31.82% | 10.34% | 46.15% | -57.14% | 59.09% |
| Nbr of stocks (in thousands) | 97,576 | 99,370 | 100,566 | 131,990 | 273,827 | 273,882 | 273,882 | 273,882 |
| Announcement Date | 3/16/22 | 3/16/23 | 3/27/24 | 3/27/25 | 3/24/26 | - | - | - |
1EUR
Estimates
| 2026 * | 2027 * | |
|---|---|---|
| P/E | -4.91x | -3.13x |
| PBR | 2.29x | 8.6x |
| EV / Sales | 16.6x | 25.1x |
| Yield | - | - |
EPS & Dividend
Y-o-Y evolution of P/E
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.6880EUR
Average target price
1.100EUR
Spread / Average Target
+59.88%
Annual profits - Rate of surprise
- Stock Market
- Stocks
- TNG Stock
- Financials Transgene
Select your edition
All financial news and data tailored to specific country editions
